Source: StreetInsider

Press Release: Eli Lilly : Taltz Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz® (ixekizumab) demonstrated greater success in key measured...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating


Read more